Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark
9 December 2014 | By Roche
cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems...
List view / Grid view
News
GSK presents asthma data that shows no additional clinical efficacy benefits for ICS-treatments with a small particle size
9 December 2014 | By GSK
GSK presented data at the British Thoracic Society meeting from a systematic analysis of 25 randomised control studies (RCTs), including a meta-analysis of three key efficacy outcomes, which explored the potential impact of the particle size of different ICS-containing asthma medicines, including Seretide/Advair (salmeterol/fluticasone proprionate) on patient outcomes...
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®
8 December 2014 | By Novartis
Sandoz, a Novartis company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's NEUPOGEN ® (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy...
Opdivo (nivolumab) demonstrates high overall response rate of 87% for treatment of relapsed or refractory Hodgkin Lymphoma
8 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced positive results from a cohort of patients in its ongoing Phase 1b trial (CheckMate -039) which evaluated PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in patients with relapsed or refractory hematological malignancies (n=23)...
Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach
8 December 2014 | By Boehringer Ingelheim
The unveiling of the new technology centre in Biberach represents the temporary completion of a remodelling and construction phase in chemical development at Boehringer Ingelheim’s largest research and development location...
XTANDI™ (enzalutamide) now approved in Europe for the treatment of men with metastatic castration-resistant prostate cancer who are chemotherapy-naive
8 December 2014 | By Astellas
Astellas Pharma Europe Ltd. announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for enzalutamide (trade name XTANDI™)...
CAMO release Service Pack 2014 for The Unscrambler® X Multivariate Data Analysis and Design of Experiments software
CAMO Software announced the launch of Service Pack 2014 for their all-in-one Multivariate Data Analysis (MVA) and Design of Experiments (DoE) software, The Unscrambler® X...
Pierre Fabre Dermatologie receives the PRIX GALIEN Award for Pharmaceutical Research for HEMANGIOL®
5 December 2014 | By Pierre Fabre
This award is recognition of both Pierre Fabre's expertise in dermatology, one of its development priorities, and of its ability to form public-private partnerships, such as that established with the University of Bordeaux...
Study shows greatest cost linked to people with depression, COPD, coronary artery disease and dementia
5 December 2014 | By Abbott
Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition...
Evgen Pharma plc intention to float on AIM
5 December 2014 | By Evgen Pharma
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its intention to join the AIM market of the London Stock Exchange by way of a Placing to raise up to £20 million...
The future of ‘Patent Boxes’ – the OECD’s adoption of a joint proposal by UK and Germany
4 December 2014 | By Deloitte
In a written ministerial statement issued, the Financial Secretary to the Treasury, Mr David Gauke, confirmed that the Organisation for Economic Cooperation and Development (OECD) has adopted all of the proposals...
VAXIMM reports positive follow-on data from oral cancer vaccine trial
Phase I study evaluating safety and tolerability of VXM01 in pancreatic cancer...
US sales of Sanofi/Regeneron’s Dupilumab for atopic dermatitis could exceed $1.3 Billion by 2022, says GlobalData Analyst
4 December 2014 | By GlobalData
The first biologic to treat atopic dermatitis, Sanofi and Regeneron’s dupilumab, could launch in the US by Q2 2017, and the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData.
Santen announces appointment of Paolo Casati as General Manager of Santen Subsidiary in Italy
4 December 2014 | By Santen
Following the launch of Santen in Italy in October 2014, Santen Italy s.r.l (Milano, Italy) (Santen) announces that Paolo Casati has been named General Manager of Santen Italy, effective November 21st, 2014...
